Fibroblast growth factors (FGF)-1 and -2 are found in most embryonic and adult normal and tumor tissues, where they are immobilized in the extracellular matrix (EM). Mobilization of these FGFs is part of a tightly controlled process resulting in the activation of highanity receptors. Recently, we have shown that a novel human FGF-binding protein (FGF-BP) mediates the release of immobilized FGF-2 from the EM. Here we isolated genomic and cDNA clones of the mouse FGF-BP homologue and studied its expression during embryonic development and skin carcinogenesis. The murine gene contains two exons that generate a 1.2 kb mRNA and predicts an 18 kDa secreted protein that is 63% identical to its human homologue. FGF-BP mRNA expression during embryogenesis is restricted to skin, intestine and lung. In the developing skin, FGF-BP expression starts at embryonic day 9, reaches peak levels perinatally and is downregulated during postnatal development. Develepment regulation in the intestine is similar, but in lungs and ovaries high expression was also observed in the adult. FGF-BP mRNA expression in the adult skin is dramatically increased during early stages of carcinogen-induced transformation in vivo and by rasactivation in vitro. Finally, mouse FGF-BP binds to FGF-2 and can function as a modulator of FGF in FGFresponsive cells. Our results suggest a potential function of FGF-BP during development and tumorigenesis.
Introduction
Fibroblast growth factors (FGFs) constitute a family of structurally homologous proteins which play important inductive roles during embryogenesis, are potent angiogenic factors in vivo and are regulators of proliferation and dierentiation for a number of cell types (reviewed e.g. in Brem and Klagsbrun, 1993; Mason, 1994) . FGF-1 and -2 (acidic and basic FGF, respectively), in contrast to most other members of the FGF-family, do not contain a signal peptide. Still, both are found complexed to low anity proteoglycan receptors of the extracellular matrix (EM), and both are widely distributed in embryonic, adult and tumor tissues. Mobilization of the dormant FGF-1 and -2 leads to their activation and facilitates binding to high anity tyrosine kinase receptors (Aviezer et al., 1994; Brem and Klagsbrun, 1993; Schlessinger et al., 1995) .
FGF-1 and -2 are expressed in a number of tumors (Esch et al., 1985; Moscatelli et al., 1986; Shing et al., 1984) but the signi®cance of this expression remains unclear since both are also found in the EM of many normal cells (Moscatelli et al., 1986; Vlodavsky et al., 1987) . A proposed function for FGF-2 in tumors might be to support tumor growth by stimulating blood vessel growth. However, there are con¯icting reports on the correlation of FGF-2 expression with vascularity in squamous cell carcinomas (SCC) of the head and neck. FGF-2 expression has been correlated with increased vascularization in some SCC (Huang et al., 1993; Schultz-Hector and Haghayegh, 1993) . Other studies reported a correlation of FGF-2 expression with enhanced dierentiation of these tumors but not with vascularization (Janot et al., 1995) .
This ambiguous correlation of FGF-2 levels to vascularity and the wide distribution of FGF-1 and -2 in embryonic as well as adult tissues and tumors suggests secondary regulatory mechanisms for their mobilization and activation. One established mobilizing mechanism involves extracellular heparitinases and proteases which attack heparansulfate chains and the proteoglycan-backbone, respectively, thereby releasing FGFs (Bashkin et al., 1989; Moscatelli, 1992; Vlodavsky et al., 1988 Vlodavsky et al., , 1991 .
A recently proposed novel pathway for FGF release from the EM involves its binding to a secreted binding protein, FGF-BP (Czubayko et al., 1994) . FGF-BP (=HBp 17) is a secreted, heparin binding protein of 17 kD molecular mass that was originally isolated from A431 human epidermoid carcinoma cells. FGF-BP binds FGF-1 and -2 in a non-covalent, reversible manner. In addition, binding of FGF-BP to FGF-2 prevents its degradation and retains its biological activity (Wu et al., 1991) .
Human FGF-BP is expressed in keratinocytes in vitro, a number of SCC-derived cell lines and in SCC tumor samples from patients (Czubayko et al., 1994; Wu et al., 1991) . Previously, we have shown that transfection of a human FGF-BP cDNA into the FGF-2 positive, anchorage dependent, non tumorigenic cell line SW-13 allows these cells to grow in soft agar and to form highly vascularized tumors in athymic nude mice (Czubayko et al., 1994) . A current working model proposes that this eect is due to FGF-BPmediated mobilization of the dormant FGF-2 that is produced by untransfected SW-13 cells. Similarly to the eect of FGF-BP-mediated mobilization of FGF-2, the addition of free FGF-2 to SW-13 cells also induces colony formation in soft agar. More recently, we observed that expression of human FGF-BP is repressed by retinoic acid transcriptionally and posttranscriptionally by altering mRNA stability (Liaudet-Coopman et al., 1996) . This suggests that the FGF-BP gene may be aected by retinoic acid modulated embryonic morphogenesis.
Because very little is known about the role of FGF-BP in carcinogenesis in vivo and during embryonic development, we studied the pattern of FGF-BP expression in a mouse model. We cloned the gene and cDNA for mouse FGF-BP. Mouse FGF-BP mRNA expression was found restricted to skin, intestine and lung during embryonic development. Its expression is downregulated in normal adult tissues but induction of skin carcinomas results in a signi®cant upregulation of FGF-BP. Furthermore, we show that the mouse and human FGF-BPs are functional homologues. Mouse FGF-BP binds FGF-2 and its expression stimulates colony formation of SW-13 cells in soft agar. We propose that FGF-BP is able to mobilize FGF-2 from its storage site in a temporally and spatially restricted manner and thus might serve as a modulator of activity of this growth factor.
Results

Cloning and characterization of the mouse FGF-BP gene
Since human FGF-BP is expressed in keratinocytes in cell culture, we started out to clone the homologous mouse cDNA from a mouse keratinocyte cDNA library (kindly provided by Dr Adam Glick, NCI). Initial attempts to clone the mouse FGF-BP cDNA by PCR using human FGF-BP derived degenerate primers failed as did cloning from a mouse keratinocyte cDNA library using human FGF-BP as a probe. We therefore chose to clone the mouse FGF-BP gene from a mouse 129SvJ lambda Gem11 genomic library. We obtained three clones with an insert size of approximately 18 kb using the coding region of the human FGF-BP cDNA as a probe. All three clones were analysed by restriction endonuclease mapping and Southern blotting and found to contain identical fragments. Overlapping restriction fragments that hybridized with the human probe were sequenced. From these data we deduced the mouse FGF-BP gene structure (Figure 1a) . The mouse FGF-BP consists of two exons that are separated by a 1.6 kb intronic sequence. The complete coding region is located on exon 2. To test the possibility that homologous genes or pseudogenes are present in the mouse genome, we performed Southern analysis under low-stringency conditions with mouse . Two identical bands of 3.8 and 0.8 kb hybridized to a full length mouse FGF-BP cDNA probe. Lane 3: BamHI digested human genomic DNA hybridized to a full length human FGF-BP cDNA probe. (c) Mouse FGF-BP gene upstream region. The ATG start codon is in bold. Transcription start (*); TATA-box and intron-splice sites (underlined); Transcription factor consensus binding sites: GRE (double underlined), AP-1 (boxed and underlined), AP-2 (boxed). The numbers are for non-intronic sequence relative to the start codon. GenBank accession numbers: U49641 and U49642
Developmental expression of a FGF-binding protein
A Kurtz et al genomic DNA, using the mouse FGF-BP coding region as a probe. The hybridization pattern of BamHI restricted mouse genomic DNA was found to be identical with that of the isolated genomic clones which were restricted with the same enzyme. Only the expected bands of 3.8 kb and 0.8 kb hybridized, suggesting the presence of only one gene (Figure 1b ). Southern analysis of BamHI restricted human genomic DNA using a human FGF-BP cDNA containing the coding region and the 3' untranslated region as a probe, detected bands of 8.0, 5.8 and 0.6 kb ( Figure  1b , lane 3), indicating sequence conservation between the two homologous genes.
To isolate the FGF-BP cDNA, 5'-and 3'-RACE PCR was performed using total RNA isolated from E16 embryos, mouse skin papillomas or carcinomas as templates. Three dierent 5'-RACE primers and two 3'-RACE primers were deduced from the genomic sequence. The primers were designed to produce overlapping fragments which would allow for the reconstruction of the complete FGF-BP RNA sequence. Ampli®ed RACE products were subcloned and the sequence obtained from the genomic clones was con®rmed.
The transcription start site as predicted by the three independent 5'-RACE products were identical and were con®rmed by primer extension analysis (data not shown) (Figure 1c) . Analysis of the potential mouse FGF-BP promoter region identi®ed a conserved TATA box 25 nucleotides upstream of the mapped transcription start site. A search for transcription factor binding site consensus sequences (TFSITE database) revealed a potential glucocorticoid response element (GRE), several E-box consensus sequences and AP-1 and AP-2 binding sites ( Figure 1c) .
Comparison of the mouse and human FGF-BP protein structure
The overall nucleotide sequence homology between the mouse and the human full-length cDNA sequences is 68%. The mouse FGF-BP cDNA predicts a 251 amino-acid protein that shows 63% amino acid identity with the human protein. When conservative substitutions were included, the similarity was 74% (Figure 2 ). Mouse and human FGF-BP also share similar charge and hydrophobic character. In particular, the positioning of 10 cysteine residues in the mature protein are conserved between mouse and human (Figure 2 ), suggesting conservation of the secondary structure. Interestingly, the mouse protein appears to be 17 amino acids longer than the human protein, creating three homology gaps when using the GCG-gap algorithm (Figure 2 ). The signal sequence cleavage site is predicted at amino acid 33 in the mouse protein which is identical to its position in the human protein. No homology with other sequences has been found in GenBank, Swissprot and other databases.
Biological function of mouse FGF-BP
In earlier studies we showed that expression of human FGF-BP stimulates colony formation of SW-13 cells in soft agar (Czubayko et al., 1994) . These cells constitutively express FGF-2 and we demonstrated that the stimulation of colony formation by hFGF-BP was due to interaction with FGF-2. To test if the human and mouse FGF-BP proteins are functional homologues, we stably transfected SW-13 cells with mFGF-BP ( Figure 3a) and assessed whether they release growth stimulatory activity upon this transfection. Figure 3b shows that colony formation is stimulated twofold by FGF-BP transfected SW-13 cells (SW-13/mBP) compared to the control transfected cells (SW-13/Co). This suggests that human and mouse FGF-BPs have similar function.
Protein ± protein interactions of mouse FGF-BP and FGF-2
To provide evidence that the FGF-BP present in the supernatants of SW-13/mBP cells can interact with FGF-2, we took advantage of the dierent elution pro®le of FGF-2 and FGF-2/ FGF-BP complexes after binding to heparin-sepharose as reported for the human FGF-BP. hFGF-BP elutes at 1 M NaCl, whereas FGF-2 elutes from heparin-sepharose at 2.0 M NaCl. The elution pro®le of FGF-2 changed after binding to FGF-BP: the FGF-BP/FGF-2 complex eluted at 1 M NaCl (Wu et al., 1991) .
Here, we used mFGF-BP enriched heparin sepharose chromatography fractions from SW-13/mBP cell supernatants and incubated them with [ (Figure 3c ). We conclude that mFGF-BP is able to bind FGF-2 and can reduce its anity for heparin very similar to hFGF-BP. 
Expression pattern of FGF-BP during mouse development
A number of growth factors and oncogenes that are upregulated during tumorigenesis play important roles in embryonic development. To investigate if FGF-BP is expressed in mouse embryos and to determine onset of expression, we performed Northern analysis of total RNA isolated from embryonic day 9 (E9) to E18 embryos ( Figure 5a ). FGF-BP mRNA (1.2 kb) was barely detectable at E9. By E12, FGF-BP transcripts became clearly detectable and increased to peak levels after E16 until E18. To determine tissue speci®city of FGF-BP expression, a multiple tissue Northern blot from newborn and adult mouse tissues was prepared. In the adult FGF-BP mRNA was barely detectable in the intestine, skin, ovaries and quite strong in lung and placenta ( Figure 4b ). Expression was below detection in heart, muscle, stomach, kidney, liver, thymus, spleen, and brain ( Figure 4b ). Comparison of FGF-BP expression in the skin and intestine of embryonic and adult mice showed a dramatic downregulation of FGF-BP in the adult skin and intestine, respectively. The dierence between transcript levels in adult skin and embryonic skin was 4 ± 5-fold (Figure 4c ), and a similar decrease of FGF-BP mRNA in adult mice was found for the intestine (not shown).
Expression of FGF-BP during skin carcinogenesis
Previous data show that FGF-BP is expressed in a variety of SCC and in normal human keratinocytes (Czubayko et al., 1994; Vellucci et al., 1995; Wu et al., 1991) . To identify conditions of FGF-BP mRNA upregulation during carcinogenesis, we compared normal primary mouse keratinocytes (MK) with murine epidermal cell lines derived from pools of 7, 12-dimethylbenz[a]anthracene (DMBA)/12-O-tetradecanoylphorbol-13-acetate (TPA) induced papillomas (SP-1 and BP-4) and a cell line derived from DMBAinitiated skin and additionally selected for resistance to Ca 2+ -induced terminal dierentiation (`308') (Strickland et al., 1988) . Furthermore, normal primary keratinocytes transduced with an activated ras gene were used (MK ras ). Cell lines SP-1, 308 and MK ras form papillomas with a low tendency for malignant progression after subcutaneous grafting onto athymic nude mice. BP-4 cells form papillomas with a high tendency of malignant progression into SCC after grafting.
Expression of FGF-BP was lowest in primary keratinocytes (MK) (Figure 4d ). In the cell lines SP-1 and 308, a 3 ± 5-fold upregulation of FGF-BP expression was observed (Figure 4d) . A less dramatic upregulation of FGF-BP expression was found in BP-4 cells (Figure 4d) .
It has been shown that skin tumor initiation with DMBA causes an activating ras-mutation in codon 61 (Balmain et al., 1984) . To test the hypothesis that ras activation plays a role for FGF-BP overexpression, we expressed activated ras in primary keratinocytes (MK ras ). The expression of activated ras resulted in a threefold upregulation of FGF-BP mRNA, comparable to that seen in SP-1 cells (Figure 4d ).
Finally we used the two-step mouse skin carcinogenesis model (Hennings, 1988) to elucidate whether FGF-BP can be induced in vivo. Normal adult mouse skin, TPA-only treated skin, low risk papillomas, high risk papillomas and SCC were compared for their levels of FGF-BP mRNA expression. Furthermore, the expression levels in tumors of these dierent stages and those in skin at dierent developmental time points were compared.
In normal adult mouse skin, FGF-BP mRNA levels were lowest (Figure 4c ). In TPA-treated adult mouse skin, FGF-BP mRNA levels were upregulated more than threefold compared to untreated skin. In DMBA/ TPA-induced low risk papillomas, upregulation of FGF-BP mRNA was about 4 ± 5-fold and is further increased in DMBA/mezerein-induced high risk papillomas (5 ± 7-fold) (Figure 4c ). In malignant SCC, upregulation of FGF-BP mRNA is less dramatic (about threefold) (Figure 4c ).
In embryonic mouse skin at E18 and in skin of newborn mice, FGF-BP mRNA levels were approximately 3 ± 5-fold higher than in adult skin ( Figure 4c ) and expression levels are comparable to those found in TPA-treated adult skin and low risk papillomas. In situ localization of FGF-BP transcripts in embryos and SCC of the skin
To localize more precisely the site of FGF-BP expression in the skin and intestine, we prepared staged embryos and DMBA/TPA-induced skin carcinoma samples for in situ hybridization using 35 S-labeled FGF-BP antisense RNA probes. We found that FGF-BP expression during all stages of development is highly restricted and was only detected in skin, lungs and intestine. In these organs FGF-BP mRNA expression increases continuously during development reaching peak levels perinatally (Figure 4a ).
In the intestine, FGF-BP transcripts were detectable at E14 in epithelial cells of the developing intestinal crypts (Figure 5a ) and are co-localized with FGF-2 mRNA expression at this stage (not shown). At E18, FGF-BP transcripts were detected in basal epithelial cells of developing intestinal crypts (Figure 5b ) and at postnatal day 7, FGF-BP transcripts were con®ned to cells at the base of intestinal villi (Figure 5c ). It appears that the intestinal epithelial precursor cells express FGF-BP and loose expression upon dierentiation.
In the skin, FGF-BP expression was found in the basal and suprabasal cell layers and hair follicles. The earliest time point studied was at E9, when FGF-BP transcripts were barely detectable in mesenchymal and epidermal structures of the body wall (not shown). At E12, FGF-BP mRNA is localized to basal cells of the subepidermal layer of the developing skin (Figure 6a ). Weak expression is also detectable in the mesenchyme underleying the epidermal layer. From E12 on, FGF-BP mRNA expression intensi®es in the developing skin. At E14, transcripts were speci®cally localized to epidermal cells of the dermal-epidermal junction and to the basal and suprabasal cell layers (Figure 6b ). Weak expression in the mesenchyme is still detectable at this stage. FGF-BP expression was correlated with hair follicle development and transcripts emerged in the developing root sheets at this stage (Figure 6b ). Expression increased continuously through E18 and was sustained at high levels until birth. At E18, expression was maintained in the basal cell layer and in the dermal-epidermal junction (Figure 6c ). High mRNA levels were seen continuously in the root sheets of the hair follicle. In the more mature hair follicles of E18 skin, the highest levels of FGF-BP transcript were con®ned to the dermal layer of the cortex adjacent to the dermal-epidermal junction (Figure 6c ). FGF-BP mRNA was detected in the dermal sheet of the hair follicle and not in the epidermis-derived central region containing the hair shaft (Figure 6c ). Expression of FGF-BP mRNA in the mesenchyme ceased completely at this stage. In the skin of newborn mice, the expression pattern and intensity seen in the basal cell layer and hair follicles of E18 skin was maintained (not shown). In contrast, FGF-BP transcripts in adult mouse skin were detected at only low levels in the basal and suprabasal cell layer and in hair follicles (Figure 6d ).
Upon induction of skin papillomas and carcinomas, FGF-BP expression is upregulated several-fold. In DMBA/TPA induced SCC, FGF-BP expression was dramatically increased within epithelial cells (Figure 6e , g, h) and comparable to expression levels in basal cells of E18 skin (Figure 6c) . No FGF-BP mRNA was detectable in other cell types such as ®broblasts or endothelial cells and very little mRNA was found in epithelial cells of normal adult skin (Figure 6d, e, g, h) . No signal was detected with the FGF-BP sense negative control probe (not shown).
Expression of FGF-2, was analysed to assess its proximity to FGF-BP expression. In skin of E14 embryos, FGF-2 expression was highest within the basal and suprabasal cell layer as well as in subepidermal mesenchyme (Figure 6f ). Expression of FGF-2 at later developmental stages becomes restricted to the dermal layer (not shown, Werner et al., 1993) . This pattern of expression overlaps partially with that of FGF-BP, which is expressed in basal cells and cells of the dermal-epidermal junction, and weakly in the mesenchyme at this stage (Figure 6b ).
Discussion
FGF-2 plays inductive roles during embryogenesis, wound healing and stimulates angiogenesis (Broadlay et al., 1989; Davidson et al., 1985; Hori et al., 1991; Shing et al., 1985) . It is found ubiquitously in adult tissues and in many tumors where it appears bound to proteoglycan molecules of the EM (Aviezer et al., 1994; Moscatelli et al., 1991) . It is only partly understood how this pleiotropic factor becomes released and available to its high anity tyrosine kinase receptor. A recently proposed mechanism describes the involvement of a secreted FGF-binding protein (FGF-BP) in the process of FGF-2 mobilization and receptor presentation (Czubayko et al., 1994) . Since FGF-BP mRNA has also been found at high levels in human SCC of the head and neck (Czubayko et al., 1994), we hypothesized that FGF-BP might facilitate local activation of FGF-2 during development and carcinogenesis. Accordingly, FGF-BP expression might correlate with carcinogenesis and development, when FGF-2 needs to be activated by release from the EM. This correlation was tested in a mouse model. The cloning of the mouse gene and cDNA revealed that the coding region for mouse FGF-BP are conserved and no structural homology with other known sequences could be found. A high degree of Figure 6 In situ analysis of FGF-BP mRNA expression during mouse skin embryonic development and in SCC of the skin. (a ± e and g ± h): FGF-BP (f): FGF-2. (a) E12; arrowheads: basal cell layer; (b) E14, arrowheads: basal cell layer; arrow: hair follicle; (c) E18, arrowheads: basal and suprabasal cell layer; asterisk: dermal layer of hair follicle cortex; arrows: root sheets of the hair follicle; (d) Adult skin, arrowhead: basal cell layer; arrow: hair follicle; (e) DMBA/TPA induced SCC of the skin (arrowhead) and adjacent tissue; (f) E14, FGF-2 expression, arrow: basal and suprabasal cell layer; arrowheads: mesenchyme; (g) DMBA/TPA induced SCC of the skin; (h) Section of (g) at higher magni®cation, arrowheads: squamous cell layer. Bars: 100 mm sequence homology of more than 85% was identi®ed within the 3'-UTR sequences of mouse and human FGF-BP mRNAs. Since 3'-UTR regions of mRNAs are frequently of regulatory signi®cance for mRNA stability and mRNA-protein interaction (Dandekar and Hentze, 1995: McCarthy and Kollmus, 1995) , this homology might also re¯ect a functional sequence element. Indeed, TPA mediated upregulation of FGF-BP mRNA might be due to a change in RNA stability (unpublished data). Similarly is the recently reported downregulation of FGF-BP mRNA levels by retinoic acid at least in part due to a modulation of mRNA stability (Liaudet-Coopman et al., 1996) .
The human and the mouse FGF-BP amino acid sequences show 74% similarity and all ten cysteines are conserved between the human and mouse proteins, indicating their importance for secondary structure formation. Our functional studies show that the degree of similarity between the mouse and human proteins is sucient to conserve functional homology. Both proteins stimulate colony formation of SW-13 cells in soft agar and both bind FGF-2.
The functions of FGF-1, which also binds to FGF-BP (Wu et al., 1991) , and FGF-2 during skin development and carcinogenesis are not clear although both are present at high levels in normal skin at all developmental stages. For the dermally and epidermally expressed FGF-1, a dual function was suggested during skin morphogenesis by stimulating basal cell proliferation and by inducing dierentiation of cells in suprabasal layers of the skin (DuCros, 1993) . FGF-2 is expressed in the dermis of normal skin (Werner et al., 1993) as well as in tissues from patients with SCC of the head and neck (Huang et al., 1993; Schultz-Hector and Haghayegh, 1993) . FGF-2 has been shown to play an essential role during wound healing (Broadley et al., 1989; Davidson et al., 1985) and to stimulate the proliferation of keratinocytes and a number of other cell types including ®broblasts and endothelial cells in vitro (Brem and Klagsbrun, 1993; Schweigerer et al., 1987) .
During skin development, FGF-2 is expressed in the mesenchyme, basal cells and in hair follicles (Figure 6f and DuCros, 1993; Schweigerer et al., 1987; Wanaka et al., 1991) , and its expression becomes restricted to the dermal layer in adult mouse skin (Werner et al., 1993) . FGF-BP expression increases in association with intensifying morphogenesis of skin layers in epithelial cells and hair follicles and continues to be high in newborn mice. Its expression decreases dramatically in the adult when morphogenetic changes are minimal and reduced to the continuous proliferation of basal cells and their successive dierentiation into spinous and granular cells. We propose that FGF-BP acts in a paracrine manner by mobilizing FGF-2 which is present in the dermal cell layer. Similarly, FGF-BP expressed in the lung and intestine can activate FGF-2 which plays inductive roles in both organs (Dignass et al., 1994; Peters et al., 1994) .
Induction of skin papillomas following the two-step DMBA/TPA carcinogenesis protocol (Hennings, 1988) caused a dramatic increase of FGF-BP transcript levels compared to normal adult skin. Steady state mRNA levels were about equally high in low and high risk papillomas and slightly less elevated after development of malignant carcinomas. Similarly, FGF-BP is expressed in vitro more strongly in cell lines SP-1 and 308, which are characterized by a low tumorigenic potential, than in cell line BP-4, which is characterized by a high tumorigenic potential. The decrease of FGF-BP expression in later progression stages of skin carcinogenesis relative to earlier stages might be due to amassing genetic alterations within tumor cells leading to growth factor independence. Alternatively, FGF-2 and FGF-BP may play a role only during early stages of tumor progression. Genetic and in vivo biological studies show indeed that benign papilloma formation and malignant progression of skin tumors are under independent control (Schultz-Hector and Haghayegh, 1993; Werner et al., 1993) . The recent identi®cation of FGF-BP by dierential display as a gene that is downregulated in SCC-derived cell lines compared to primary normal human keratinocytes in vitro (Vellucci et al., 1995) might also be due to the acquisition of a growth factor independent tumor phenotype of the cells used in this assay.
Our data indicate that the ras-activated signal transduction pathway is a regulator of FGF-BP gene transcription. DMBA treatment of skin causes mutations at codon 61 of the ras gene leading to rasactivation (Balmain et al., 1984; Hennings et al., 1988) and FGF-BP expression is increased in DMBA/TPA induced papillomas and in cell lines MK ras , SP1 and 308 that carry an activated ras gene. In addition, FGF-BP mRNA levels are upregulated in mouse skin after application of the PKC-activator TPA alone. Both, activation of PKC and of ras may result in AP-1 jun/ fos heterodimer activation. Involvement of AP-1 in skin carcinogenesis is indicated by activation of fos in keratinocytes resulting in a carcinoma phenotype and the complete inability of c-fos negative papillomas to progress into malignant skin carcinomas (Saez et al., 1995) . An AP-1 consensus binding sequence is present within the FGF-BP promoter region and its functionality is currently being tested.
In conclusion, our results show an intriguing correlation of FGF-BP expression with skin development and with early stages of skin carcinogenesis. This regulation might be driven by signals transduced by the ras/PKC pathway. Our ®ndings are in agreement with the initial hypothesis that FGF-BP is involved in local activation of the ubiquitously expressed FGF-2.
Materials and methods
Animals and cell lines
SENCAR mice were used for DMBA/TPA carcinogenesis experiments as described in (Hennings, 1988) . BALB/c mice were used for embryonic and adult tissue expression studies. Staging of embryos was based on time of mating, where the day after mating was day E1. Primary keratinocytes (MK) were derived from SENCAR mice. Cell lines SP-1 and BP-4 were derived from pools of papillomas produced on SENCAR and BALB/c mouse skin, respectively, by DMBA-initiation and TPA promotion. Cell line 308 was derived from BALB/c mouse skin initiated in vivo with DMBA and selection of cells in culture for resistance to Ca 2+ -induced terminal differentiation. All cell lines except for MK contain an activated ras HA gene carrying a mutation within codon 61 (Strickland al., 1988) . MK cultures were transduced with a replication-defective retrovirus expressing activated ras HA as described (Roop et al., 1986) , and are referred to as MK-ras cells. SW-13 human epithelial cells were maintained in IMEM medium containing 10% FBS.
Induction of epidermal tumors
Skin papillomas and carcinomas were chemically induced on SENCAR mice by the two-stage tumorigenesis schedule (Hennings et al., 1983) . Brie¯y, 6 ± 8 week old mice receive a topical application of DMBA (25 mg) as the tumor initiator on their dorsal skin, followed by repeated weekly applications of TPA (2 mg) as the tumor promoter for up to 40 weeks (Hennings, 1988) . Acetone was the vehicle for all topically applied chemicals. This protocol results in the formation of multiple benign papillomas which have a low risk for malignant progression into carcinomas. To produce high risk papillomas, promotion was performed using mezerein (4 mg, twice weekly) (Hennings et al., 1985) . Low risk papillomas were excised at 11 weeks of promotion. High risk papillomas were excised at 8 weeks, at the time of ®rst detection (1 ± 2 mm in diameter). Tumors were immediately embedded in OTC (Tissue-TEK) and frozen on dry ice. Other tumors were snapfrozen in liquid nitrogen and stored at 7808C for later RNA extraction.
Genomic cloning, Southern analysis and sequencing
About 5610 5 plaques of an ampli®ed LambdaGEM-11 mouse strain 129 genomic library (constructed by H Hellmich, NIH) were transferred to nylon membranes and screened with a 32 P-labeled human FGF-BP polymerase chain reaction (PCR) fragment containing the complete coding region. Hybridization and wash steps were performed as described in (Sambrook et al., 1989) . Brie¯y, hybridization was at 378C in hybridization buer containing 50% formamide, 66SSC, 10 mg/ml ssDNA, 0.1% SDS, and 56 Denhardt's solution, for 16 h. Filters were subsequently washed twice at 428C and 508C in 26SSC/0.1% SDS for 20 min each. Autoradiography was overnight at 7708C using intensifying screens and Hyper®lm MP (Amersham). Three clones were identi®ed and shown to be identical by restriction enzyme analysis. Clone mBP7 was chosen for further analysis and cleaved with restriction enzymes BamHI and SacI and all fragments were subcloned into pGEM-7Z (Promega). Subclones containing fragments that hybridized with the human FGF-BP probe were selected and sequenced using Sequenase (USB) and PCR-based automated sequencing (Applied Biosystems).
Southern analysis of 20 mg of BamHI restricted mouse 129 genomic DNA and 1 mg lambda-clone mBP7 DNA was performed as described in (Sambrook et al., 1989) . Filters were hybridized to a mouse FGF-BP cDNA probe. Hybridization was for 24 h at 378C in hybridization buer, containing 40% formamide. Filters were washed in 16SSC, 0.1% SDS at 378C for 20 min and at 558C for 20 min and autoradiographed for 48 h using BioMax ®lm (Amersham).
RACE PCR and cDNA cloning
Total RNA was extracted using RNAStat (Tel-Test Inc) from DMBA/TPA induced mouse skin papillomas, carcinomas and normal E16 mouse embryos and reverse transcribed using Superscript reverse transcriptase (Gibco/ BRL). 5'-and 3'-RACE (rapid ampli®cation of complementary DNA ends) PCR was performed using the AmpliFINDER RACE kit protocol (Clontech). Speci®c nested oligonucleotides were derived from the putative coding region of the genomic sequence. (5'Race-primer 1:
5'-GACTTCATTAGCATGATGT-3', 5'RACE primer 2: 5'-TGAGTAGCCAGGAGAAG-3', 5'RACE primer 3: 5'-GATGTCCTGCTTCTCTGC-3'; 3'RACE primer 1: 5'-CTTGGAGCTCCATTTGCAC-3'). The PCR products were subcloned into the TA-cloning vector pCRII (Invitrogen) and sequenced using Sequenase (USB). The coding region of 754 bp was ampli®ed from E16 embryonic cDNA using 5' primer: 5'-GTGATGAGACTCCACA-3' and 3' primer: 5'-TTAGCATGATGTCGCCT-3', the ampli®ed fragment was cloned into pCRII and sequenced using Sequenase. This fragment was used as a probe for all Northern hybridization experiments.
Primer extension
Primer extension was carried out using Promega AMV Reverse Transcriptase Primer Extension Kit according to the manufacturer's protocol. Brie¯y, oligonucleotides that were used for 5'-RACE PCR (see above) or a kanamycin control primer were labeled with [a-32 P]ATP (3,000 Ci/ mmol, Amersham) using T4 polynucleotide kinase. Labeled primer and either 2 ng of 1.2 kb kanamycin RNA or 0.5 mg poly(A) + RNA from E16 mouse embryos were annealed at 558C for 20 min. Reverse transcription reaction was carried out for 30 min at 41 ± 428C. Primer extension products were run on a 6% polyacrylamide sequencing gel and autoradiography was performed for 16 h.
Northern blot analysis
Northern blots were prepared from 30 mg total RNA isolated from various mouse tissues, tumor samples, cell lines and mouse embryos using RNAStat (Tel-Test Inc). Blots were probed with a mouse FGF-BP cDNA probe containing the complete coding region. For quanti®cation, the blots were stripped and reprobed with glyceraldehyde 3-phosphate dehydrogenase (GPDH) cDNA probe (Clontech). Transcript levels of this ubiquitously expressed housekeeping gene are refractory to a number of inducing agents, including cytokines and TPA. Probes were prepared by random-priming with [a 32 P]dCTP (Amersham). Hybridization was carried out in hybridization buer containing 50% formamide at 428C. Blots were subsequently washed in 0.16SSC at 608C prior to exposure to phosphorimaging plates (Molecular Dynamics). Phosphorimaging plates were scanned (Phosphorimager 445S1) and quanti®ed using ImageQuant software (Molecular Dynamics).
In situ hybridization
In situ hybridization was performed following standard procedures using 35 S-labeled sense and antisense mouse FGF-BP and antisense FGF-2 riboprobes. Brie¯y, a 754 bp mouse FGF-BP fragment, containing the complete coding region, was transcribed in sense and antisense orientation using Sp6 and T7 polymerases, respectively, yielding a speci®c activity of 410 9 c.p.m./mg probe. For FGF-2, a 350 bp cDNA fragment was used for transcription. 6 mm sections of frozen mouse skin, papilloma and carcinoma tissue as well as mouse embryos were prepared on silanized slides (Oncor), ®xed in 4% paraformaldehyde and stored in 70% ethanol at 48C. Before hybridization, sections were rehydrated in 26SSC, acetylated in 0.25% acetic anhydrate, 0.1% triethanolamine, pH 8.0, followed by immersing slides for 30 min in 0.1 M Tris-HCl, (pH 7.0), 0.1 M glycine. Sections were hybridized in hybridization solution (26SSC, 50% formamide, 10% dextran, 10 mM DTT, 1 mg/ml tRNA, 1 mg/ml ssDNA, 2 mg/ml BSA, and 1610 6 c.p.m. of 35 S labeled probe/10 ml) for at least 3 h at 558C. Finally, slides were washed in 26SSC/50% formamide at 528C for 30 min, rinsed in 26SSC followed by incubation in RNAse A (100 mg/ml) for 30 min at 378C. Slides were washed subsequently in 26SSC/50% formamide, immersed in 26SSC and dehydrated in ethanol. Dried slides were dipped in LM-1 photoemulsion (Amersham) and exposed for 7 days at 48C in the dark, developed and counterstained with hematoxylin and eosin.
Generation of mouse FGF-BP expressing cell lines
For functional studies of mouse FGF-BP we generated an expression plasmid using the pRC/CMV vector (Invitrogen). A full length cDNA fragment of mFGF-BP was cloned into the BstXI restriction site of pRC/CMV, resulting in vector pRC/mBP. Correct integration was veri®ed by DNA sequencing. pRC/mBP and the parental vector, pRC/CMV were transfected into SW-13 cells using lipofectamin (Gibco/BRL). Brie¯y, approximately 10 6 cells were incubated with lipofectamin/plasmid mixture for 6 h at 378C in Opti-MEM (Gibco/BRL). The medium was replaced with growth medium and 24 h later G418 at 350 mg/ml was added for clonal selection. G418 resistant cells were collected and analysed for mFGF-BP expression by Northern analysis. SW-13/mBP cells expressed high levels of FGF-BP and were used for further analysis. As control, G418-resistant SW-13 cells transfected with the original plasmid pRC/CMV were used (SW-13/Co).
Soft agar assay
Studies of anchorage independent growth of SW-13 cells in soft agar were carried out as described (Czubayko et al., 1994) . Brie¯y, 20,000 SW-13 cells in 0.8 ml of 0.35% agar (Bactoagar Life Technologies) were layered on top of 1 ml of a solidi®ed 0.6% agar layer in a 35 mm dish. 10 000 SW-13/mBP or SW-13 cells transfected with the control vector (SW-13/Co) were used as a feeder layer. Growth medium with 10% fetal bovine serum was included in both agar layers. Colonies more than 60 mm in diameter were counted after 14 days of incubation using an image analyser. Experiments were carried out in triplicate sets of 35 mm dishes.
Concentration of heparin binding proteins from conditioned media
Media conditioned by SW-13 cells stably transfected with either pRC/mBP or the empty vector were collected and loaded onto heparin Sepharose columns (Pharmacia) preequilibrated with phosphate buered saline (PBS). The columns were washed with PBS and bound proteins were eluted successively with a step gradient of 0.5, 1.0, 1.5, and 2.0 M NaCl in 10 mM Tris buer (pH 7.5). FGF-BP containing 1.0 M fractions were used for further analysis.
[
I]FGF-2 binding assay
One milliliter of the 1.0 M heparin anity chromatography fractions, derived from 30 ml of conditioned medium of 10 7 FGF-BP producing SW-13/mBP cells and control cells, respectively, were diluted 1 : 5 in PBS containing 0.5% bovine serum albumin (BSA) and incubated with 500 000 c.p.m. of [ 125 I]hFGF-2 (Amersham) for 1 h at room temperature in the presence or absence of 20 ng unlabeled hFGF-2 (Amersham). Following the binding step, heparin Sepharose (150 ml gel bed) was added and the samples were incubated in a rotary shaker for 30 min at 48C. Proteins were eluted after extensive washing in PBS with 400 ml of 0.5, 0.75, 1.0, 1.5, and 2.0 M NaCl. The eluted fractions were counted in a gamma counter for the presence of [
125 I]hFGF-2 and analysed on a 10% SDSpolyacrylamid gel. For electrophoresis, fractions were desalted by dialysis and lyophilized. The lyophilized proteins were redissolved in 100 ml loading buer containing b-mercaptoethanol. 25 ml were used for electrophoresis and the gel analysed by autoradiography.
